Suppr超能文献

《钟声为谁而鸣:完善心源性猝死风险评估》。

For Whom the Bell Tolls : Refining Risk Assessment for Sudden Cardiac Death.

机构信息

Hadassah Medical Center, Heart Institute, Hebrew University in Jerusalem Medical School, Kyriat Hadassah, PO Box 12000, 91120, Jerusalem, Israel.

Heart Research Follow-up Program, Division of Cardiology, Department of Medicine at the University of Rochester Medical Center, Rochester, NY, USA.

出版信息

Curr Cardiol Rep. 2019 Aug 2;21(9):106. doi: 10.1007/s11886-019-1191-z.

Abstract

Sudden cardiac death is one of the most important causes of death worldwide. Advancements in medical treatment, percutaneous interventions, and device therapy (ICD and CRTD) showed consistent reduction in mortality, mainly in survivors of SCD and in patients with ischemic cardiomyopathy and depressed left ventricular function. Patients with non-ischemic cardiomyopathies, mildly reduced LV function, and channelopathies have increased risk for SCD. Identifying the subgroup of these patients before they experience life-threatening or fatal events is essential to further improve outcomes. In this review, we aimed to summarize the current knowledge for risk stratification and primary prevention, to describe the gaps in evidence, and to discuss future directions for screening and treating patients at risk for SCD. PURPOSE OF REVIEW: The purpose of this review is to provide a comprehensive description of the etiologies of sudden cardiac death, risk stratification strategies, and to describe the current medical and interventional therapies. We aimed to discuss the current gaps in our knowledge of primary prevention of SCD and to review novel approaches and interventions. RECENT FINDINGS: The incidence of SCD has decreased in the last two decades due to improved pharmacological treatment and ICD implantation in SCD survivors and in patients with reduced left ventricular function and ischemic cardiomyopathy. The efficacy of ICD in patients with non-ischemic cardiomyopathy is challenged by new findings from the DANISH trial. Catheter ablation is new emerging strategy to prevent SCD in patients with scar relater or PVC-triggered ventricular arrhythmias. Despite the new treatments, SCD is still a major burden. ICD remains the cornerstone for patients with ischemic cardiomyopathy, whereas appropriate risk stratification of the patients with non-ischemic cardiomyopathy and channelopathies is needed to further improve outcomes. The future of ablation as the treatment and prevention of SCD remains to be studied.

摘要

心脏性猝死是全球最重要的死亡原因之一。医学治疗、经皮介入和器械治疗(ICD 和 CRTD)的进步使死亡率持续下降,主要是在心脏性猝死幸存者和缺血性心肌病及左心室功能降低患者中。非缺血性心肌病、左心室功能轻度降低和通道病患者发生心脏性猝死的风险增加。在这些患者发生危及生命或致命事件之前识别出亚组患者,对于进一步改善结局至关重要。在这篇综述中,我们旨在总结目前用于风险分层和一级预防的知识,描述证据中的空白,并讨论筛查和治疗心脏性猝死风险患者的未来方向。

综述目的

本综述的目的是全面描述心脏性猝死的病因、风险分层策略,并描述目前的医学和介入治疗方法。我们旨在讨论心脏性猝死一级预防知识中的当前空白,并回顾新方法和干预措施。

最近发现

由于改善了药理学治疗和 ICD 在心脏性猝死幸存者以及左心室功能降低和缺血性心肌病患者中的应用,过去二十年心脏性猝死的发生率有所下降。DANISH 试验的新发现对 ICD 在非缺血性心肌病患者中的疗效提出了挑战。导管消融是预防与疤痕相关或 PVC 触发的室性心律失常患者心脏性猝死的新出现策略。尽管有了新的治疗方法,但心脏性猝死仍然是一个主要负担。ICD 仍然是缺血性心肌病患者的基石,而需要对非缺血性心肌病和通道病患者进行适当的风险分层,以进一步改善结局。消融作为治疗和预防心脏性猝死的未来仍有待研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验